title: [Pharmacological treatment of the irritable bowel syndrome: a technical review].
abstract: BACKGROUND
  The goal of a comprehensive treatment in irritable bowel syndrome (IBS) patients should be the improvement of symptoms and improve the quality of life.
  
  
  OBJECTIVE
  To review the drugs recommended in IBS, their mechanisms of action, side effects, risks and benefits, contraindications, availability in our country and the evidence supporting their use.
  
  
  METHODS
  A technical and narrative review which evaluated the articles published in national and world literature regarding the pharmacological treatment of IBS was performed. PubMed and IMBIOMED electronic databases were searched (until September 2009) using all descriptors regarding IBS and drug therapy.
  
  
  RESULTS
  There is enough clinical evidence to recommend the use of antispasmodics (alone orin combination) and tricyclic antidepressants for pain treatment in IBS. Laxatives are useful in the management of chronic constipation, but there is little evidence in the management of IBS. Although, antiflatulents and antidiarrheals are widely used there is little information supporting its use. The use of a nonabsorbable antibiotic (rifaximin) is effective in a subgroup of IBS patients. Serotoninergics drugs have proven effective in relieving symptoms of IBS; however, these drugs require caution in their use. There are studies have shown that probiotics improve some symptoms of IBS.
  
  
  CONCLUSIONS
  There are many effective treatment options in the symptomatic management of IBS. The choice of treatment should be based on the predominant symptoms of each patient.
authors.affiliation: Laboratorio de Fisiología Digestiva y Motilidad Gastrointestinal, Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana. Veracruz, Ver. jose.remes.troche@gmail.com
authors.forename: J M
authors.initials: JM
authors.lastname: Remes-Troche
authors.forename: O
authors.initials: O
authors.lastname: Gómez-Escudero
authors.forename: J R
authors.initials: JR
authors.lastname: Nogueira-de Rojas
authors.forename: R
authors.initials: R
authors.lastname: Carmona-Sánchez
authors.forename: J
authors.initials: J
authors.lastname: Pérez-Manauta
authors.forename: A
authors.initials: A
authors.lastname: López-Colombo
authors.forename: J L
authors.initials: JL
authors.lastname: Sanjurjo-García
authors.forename: A
authors.initials: A
authors.lastname: Noble-Lugo
authors.forename: J A
authors.initials: JA
authors.lastname: Chávez-Barrera
authors.forename: M
authors.initials: M
authors.lastname: González-Martínez
mesh_terms: D000527:Alprostadil / Q000031:analogs & derivatives / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000930:Antidiarrheals / Q000627:therapeutic use; D000934:Antifoaming Agents / Q000627:therapeutic use; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D054368:Laxatives / Q000627:therapeutic use; D000068238:Lubiprostone; D010276:Parasympatholytics / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use; D018490:Serotonin Agents / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000930:Antidiarrheals; D000934:Antifoaming Agents; D054368:Laxatives; D010276:Parasympatholytics; D011619:Psychotropic Drugs; D018490:Serotonin Agents; D000068238:Lubiprostone; D000527:Alprostadil